New option listings for January 8th include FibroGen Inc (KYNB). Option delistings effective January 8th include FibroGen (FGEN).
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on FGEN:
- FibroGen rebrands as Kyntra Bio, refocuses on oncology
- FibroGen announces rebrand as Kyntra Bio
- FibroGen granted orphan drug designation for roxadustat in MDS
- FibroGen’s Earnings Call: Strategic Moves Amid Financial Caution
- FibroGen’s Strategic Moves and Financial Outlook: Hold Rating Amid Uncertainties